IDEAYA Biosciences, Inc.

Listed Company

IDYACIK 0001676725NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$218.71M

Net Income

$-113.70M

Total Assets

$1.11B

Equity

$1.02B

Shares Out

87.86M

Op. Cash Flow

$-71.10M

IDYA$36.02+62.89% · past yearDBEQ Basic

Daily closing prices

Business

IDEAYA Biosciences is a precision medicine oncology company developing small-molecule and antibody-drug conjugate therapies for genetically defined solid tumors. The company's pipeline includes nine clinical-stage candidates across four focus areas: darovasertib (PKC inhibitor for uveal melanoma), ADC/DDR pathway combinations (IDE849, IDE161), MTAP-pathway inhibitors (IDE397, IDE892), and next-generation therapies (IDE574, IDE275). IDEAYA markets in the United States and selectively partners with major pharmaceutical companies including Pfizer, Gilead, Servier, Hengrui Pharma and others for clinical development and commercialization.

Summary from 10-K filed 2026-02-17

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Collaboration revenue	219	7	23	51	28
Research and development	315	295	130	90	58
General and administrative	63	39	28	24	20
Total operating expenses	378	334	158	113	78
Loss from operations	−159	−327	−134	−63	−50
Interest income and other income, net	46	52	21	4	506,000
Net loss	−114	−274	−113	−59	−50
Unrealized gains on marketable securities	1	250,000	3	−2	−719,000
Comprehensive loss	−112	−274	−110	−61	−50
Net loss per common share, basic	−1.28	−3.36	−1.96	−1.42	−1.41
Net loss per common share, diluted	−1.28	−3.36	−1.96	−1.42	−1.41
Weighted-average number of common shares outstanding used in computing net loss per share, basic	88	82	58	41	35
Weighted-average number of common shares outstanding used in computing net loss per share, diluted	88	82	58	41	35

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	113	84	157	69	92
Short-term marketable securities	527	592	368	296	155
Prepaid expenses and other current assets	21	13	8	5	3
Contract assets	6	0	—	—	—
Total current assets	667	690	533	370	251
Restricted cash	1	805,000	757,000	106,000	106,000
Long-term marketable securities	410	406	107	8	121
Property and equipment, net	8	9	6	7	5
Right-of-use assets	23	19	2	2	4
Total assets	1,109	1,124	649	388	381
Accounts payable	18	15	7	4	2
Accrued liabilities	41	30	19	17	12
Operating lease liabilities, current	339,000	298,000	2	2	2
Total current liabilities	59	46	27	32	45
Long-term operating lease liabilities	28	19	1	2	3
Total liabilities	86	65	28	39	80
Commitments and contingencies (Note 6)	—	—	—	—	—
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; no shares issued and outstanding as of December 31, 2025 and December 31, 2024	—	—	—	—	—
Common stock, $0.0001 par value, 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 87,796,561 and 86,503,509 shares issued and outstanding as of December 31, 2025 and December 31, 2024	9,000	9,000	7,000	5,000	4,000
Additional paid-in capital	1,757	1,681	969	588	479
Accumulated other comprehensive income	2	812,000	562,000	−3	−712,000
Accumulated deficit	−737	−623	−348	−235	−177
Total stockholders equity	1,023	1,059	621	349	302
Total liabilities and stockholders equity	1,109	1,124	649	388	381

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−114	−274	−113	−59	−50
Depreciation and amortization	3	2	2	2	2
Net amortization (accretion) of premiums (discounts) on marketable securities	−10	−23	−12	−695,000	2
Stock-based compensation	46	35	18	12	8
Amortization of right of use assets	2	1	2	1	1
Accounts receivable	0	0	193,000	892,000	774,000
Prepaid expenses and other assets	−8	−6	−2	−2	−189,000
Accounts payable	3	8	3	2	1
Accrued and other liabilities	10	11	2	5	4
Contract assets and liabilities	−6	0	−14	—	—
Lease liabilities	3	−1	−2	−2	−2
Net cash used in operating activities	−71	−248	−115	−87	−56
Purchases of property and equipment, net	−2	−4	−2	−3	−3
Purchases of marketable securities	−608	−1,191	−596	−256	−315
Maturities of marketable securities	680	693	440	226	244
Net cash provided by (used in) investing activities	70	−503	−158	−33	−70
Proceeds from issuance of common stock in public offering, net of issuance costs	0	274	281	86	86
Proceeds from issuances of pre-funded warrants	0	9	42	0	0
Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs	25	380	29	9	57
Proceeds from exercise of common stock options	3	12	10	1	2
Proceeds from ESPP purchases	1	1	1	755,000	697,000
Net cash provided by financing activities	30	678	363	97	145
Net increase (decrease) in cash, cash equivalents and restricted cash	29	−73	89	−23	20
Cash paid for interest	0	25,000	69,000	60,000	71,000
Right-of-use asset obtained in exchange for a new operating lease liability	6	18	1	0	0
Purchases of property and equipment in accounts payable and accrued liabilities	1	1	147,000	384,000	92,000
Unpaid offering costs	0	0	43,000	39,000	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is IDEAYA Biosciences, Inc.'s CIK number?

IDEAYA Biosciences, Inc.'s SEC CIK number is 0001676725 (1676725). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find IDEAYA Biosciences, Inc.'s SEC filings?

All of IDEAYA Biosciences, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did IDEAYA Biosciences, Inc. last report earnings?

IDEAYA Biosciences, Inc. (IDYA) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-204944). This is IDEAYA Biosciences, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is IDEAYA Biosciences, Inc.'s most recent earnings 8-K?

IDEAYA Biosciences, Inc.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001193125-26-204944. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View IDEAYA Biosciences, Inc.'s latest earnings 8-K →
Look up any company's CIK number →